<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04900597</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-P00037093</org_study_id>
    <nct_id>NCT04900597</nct_id>
  </id_info>
  <brief_title>Effect of Blenderized Enteral Tube Feeds on Pediatric Upper Gastrointestinal Tract Physiology</brief_title>
  <official_title>Effect of Blenderized Enteral Tube Feeds on Pediatric Upper Gastrointestinal Tract Physiology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Blenderized diets consist of a wide range of table foods such as fruits, vegetables, meat and&#xD;
      legumes, pureed in a blender and administered via gastrostomy tube. In a recent study, the&#xD;
      investigators reported that children receiving blenderized feeds via gastrostomy had fewer&#xD;
      total admissions and respiratory admissions, total emergency room visits, and improved&#xD;
      gastrointestinal symptom scores compared to those fed formula. The goal of this project is to&#xD;
      understand how these diets affect gastroesophageal reflux burden.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hypothesize that rates of gastroesophageal reflux will be lower in&#xD;
      blenderized diets compared to formula. The investigators will determine if reflux burden as&#xD;
      measured by multichannel intraluminal impedance/esophageal pH monitoring performed for&#xD;
      clinical purposes differs between low viscosity conventional formula, medium viscosity&#xD;
      commercial blenderized diet, and high viscosity commercial blenderized diet in 45 children&#xD;
      receiving conventional formula via gastrostomy. All participants will receive each of the&#xD;
      three test diets in random order in a 3-way crossover design. Results of gastric emptying&#xD;
      scans will be recorded if done for clinical purposes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reflux episodes</measure>
    <time_frame>4 hours (following feed)</time_frame>
    <description>Number of total reflux episodes (acid and non-acid) by impedance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Full column reflux episodes</measure>
    <time_frame>4 hours (following feed)</time_frame>
    <description>Total number of full-column reflux episodes by impedance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of time esophageal pH &lt; 4</measure>
    <time_frame>4 hours after feed</time_frame>
    <description>Percent of time esophageal pH &lt; 4 by impedance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average height of refluxate</measure>
    <time_frame>4 hours after feed</time_frame>
    <description>Average height of refluxate by impedance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of symptoms</measure>
    <time_frame>4 hours after feed</time_frame>
    <description>Frequency of pulmonary and gastrointestinal symptoms from questionnaires during impedance</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Gastric emptying (percent of ingested contents remaining in stomach at 1 hour)</measure>
    <time_frame>1 hour</time_frame>
    <description>Gastric emptying scans by scintigraphy will be analyzed if performed for clinical reasons</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Enteral Feeding Intolerance</condition>
  <arm_group>
    <arm_group_label>Elecare - Nourish - Real Foods Blends</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elecare for first bolus, Nourish for second bolus, Real Foods Blends for third bolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nourish - Real Foods Blends - Elecare</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nourish for first bolus, Real Foods Blends for second bolus, Elecare for first bolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Real Foods Blends - Elecare - Nourish</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Real Foods Blends for first bolus, Elecare for second bolus, Nourish for third bolus</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Elecare Jr</intervention_name>
    <description>Elecare Jr is a standard pediatric elemental formula</description>
    <arm_group_label>Elecare - Nourish - Real Foods Blends</arm_group_label>
    <arm_group_label>Nourish - Real Foods Blends - Elecare</arm_group_label>
    <arm_group_label>Real Foods Blends - Elecare - Nourish</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nourish</intervention_name>
    <description>Nourish is a commercially prepared blenderized tube feed that is formulated for pediatric use</description>
    <arm_group_label>Elecare - Nourish - Real Foods Blends</arm_group_label>
    <arm_group_label>Nourish - Real Foods Blends - Elecare</arm_group_label>
    <arm_group_label>Real Foods Blends - Elecare - Nourish</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Real Foods Blends</intervention_name>
    <description>Real Foods Blends is a commercially prepared blenderized tube feed that is formulated for pediatric use</description>
    <arm_group_label>Elecare - Nourish - Real Foods Blends</arm_group_label>
    <arm_group_label>Nourish - Real Foods Blends - Elecare</arm_group_label>
    <arm_group_label>Real Foods Blends - Elecare - Nourish</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 1-21 years&#xD;
&#xD;
          -  G-tube&#xD;
&#xD;
          -  Able to tolerate bolus gastric feeds over 30 minutes&#xD;
&#xD;
          -  Use of conventional enteral formula&#xD;
&#xD;
          -  Undergoing impedance study for clinical purposes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of allergy or intolerance to any component of the test diets&#xD;
&#xD;
          -  History of Nissen fundoplication&#xD;
&#xD;
          -  Current use of non-invasive pressure support (continuous or bi-level positive airway&#xD;
             pressure)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bridget M Hron, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bridget M Hron, MD</last_name>
    <phone>6173556058</phone>
    <email>bridget.hron@childrens.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bridget M Hron, MD</last_name>
      <phone>617-355-1433</phone>
      <email>bridget.hron@childrens.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>May 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children's Hospital</investigator_affiliation>
    <investigator_full_name>Bridget Hron</investigator_full_name>
    <investigator_title>Staff Physician</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

